279 related articles for article (PubMed ID: 30733559)
21. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice.
Tasfaout H; Buono S; Guo S; Kretz C; Messaddeq N; Booten S; Greenlee S; Monia BP; Cowling BS; Laporte J
Nat Commun; 2017 Jun; 8():15661. PubMed ID: 28589938
[TBL] [Abstract][Full Text] [Related]
22. Centronuclear myopathies: a widening concept.
Romero NB
Neuromuscul Disord; 2010 Apr; 20(4):223-8. PubMed ID: 20181480
[TBL] [Abstract][Full Text] [Related]
23. Centronuclear Myopathy Caused by Defective Membrane Remodelling of Dynamin 2 and BIN1 Variants.
Fujise K; Noguchi S; Takeda T
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682949
[TBL] [Abstract][Full Text] [Related]
24. Sporadic centronuclear myopathy with muscle pseudohypertrophy, neutropenia, and necklace fibres due to a DNM2 mutation.
Romero NB; Bevilacqua JA; Oldfors A; Fardeau M
Neuromuscul Disord; 2011 Feb; 21(2):148; author reply 148-9. PubMed ID: 21247764
[No Abstract] [Full Text] [Related]
25. DNM2 mutations in Chinese Han patients with centronuclear myopathy.
Lin P; Liu X; Zhao D; Dai T; Wu H; Gong Y; Yan C
Neurol Sci; 2016 Jun; 37(6):995-8. PubMed ID: 26908122
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy.
Fischer D; Herasse M; Bitoun M; Barragán-Campos HM; Chiras J; Laforêt P; Fardeau M; Eymard B; Guicheney P; Romero NB
Brain; 2006 Jun; 129(Pt 6):1463-9. PubMed ID: 16585051
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen improves muscle structure and function of Bin1- and Dnm2-related centronuclear myopathies.
Gineste C; Simon A; Braun M; Reiss D; Laporte J
Brain; 2023 Jul; 146(7):3029-3048. PubMed ID: 36562127
[TBL] [Abstract][Full Text] [Related]
28. A centronuclear myopathy--dynamin 2 mutation impairs autophagy in mice.
Durieux AC; Vassilopoulos S; Lainé J; Fraysse B; Briñas L; Prudhon B; Castells J; Freyssenet D; Bonne G; Guicheney P; Bitoun M
Traffic; 2012 Jun; 13(6):869-79. PubMed ID: 22369075
[TBL] [Abstract][Full Text] [Related]
29. Subtle central and peripheral nervous system abnormalities in a family with centronuclear myopathy and a novel dynamin 2 gene mutation.
Echaniz-Laguna A; Nicot AS; Carré S; Franques J; Tranchant C; Dondaine N; Biancalana V; Mandel JL; Laporte J
Neuromuscul Disord; 2007 Dec; 17(11-12):955-9. PubMed ID: 17825552
[TBL] [Abstract][Full Text] [Related]
30. Calcium homeostasis alterations in a mouse model of the Dynamin 2-related centronuclear myopathy.
Fraysse B; Guicheney P; Bitoun M
Biol Open; 2016 Nov; 5(11):1691-1696. PubMed ID: 27870637
[TBL] [Abstract][Full Text] [Related]
31. Dynamin 2 the rescue for centronuclear myopathy.
Demonbreun AR; McNally EM
J Clin Invest; 2014 Mar; 124(3):976-8. PubMed ID: 24569368
[TBL] [Abstract][Full Text] [Related]
32. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations.
Böhm J; Biancalana V; Malfatti E; Dondaine N; Koch C; Vasli N; Kress W; Strittmatter M; Taratuto AL; Gonorazky H; Laforêt P; Maisonobe T; Olivé M; Gonzalez-Mera L; Fardeau M; Carrière N; Clavelou P; Eymard B; Bitoun M; Rendu J; Fauré J; Weis J; Mandel JL; Romero NB; Laporte J
Brain; 2014 Dec; 137(Pt 12):3160-70. PubMed ID: 25260562
[TBL] [Abstract][Full Text] [Related]
33. Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.
Trochet D; Prudhon B; Beuvin M; Peccate C; Lorain S; Julien L; Benkhelifa-Ziyyat S; Rabai A; Mamchaoui K; Ferry A; Laporte J; Guicheney P; Vassilopoulos S; Bitoun M
EMBO Mol Med; 2018 Feb; 10(2):239-253. PubMed ID: 29246969
[TBL] [Abstract][Full Text] [Related]
34. Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation.
Cowling BS; Prokic I; Tasfaout H; Rabai A; Humbert F; Rinaldi B; Nicot AS; Kretz C; Friant S; Roux A; Laporte J
J Clin Invest; 2017 Dec; 127(12):4477-4487. PubMed ID: 29130937
[TBL] [Abstract][Full Text] [Related]
35. Clinical, pathological, and genetic features of dynamin-2-related centronuclear myopathy in China.
Chen T; Pu C; Wang Q; Liu J; Mao Y; Shi Q
Neurol Sci; 2015 May; 36(5):735-41. PubMed ID: 25501959
[TBL] [Abstract][Full Text] [Related]
36. A mutation associated with centronuclear myopathy enhances the size and stability of dynamin 2 complexes in cells.
James NG; Digman MA; Ross JA; Barylko B; Wang L; Li J; Chen Y; Mueller JD; Gratton E; Albanesi JP; Jameson DM
Biochim Biophys Acta; 2014 Jan; 1840(1):315-21. PubMed ID: 24016602
[TBL] [Abstract][Full Text] [Related]
37. Dynamin-2 reduction rescues the skeletal myopathy of a SPEG-deficient mouse model.
Li Q; Lin J; Widrick JJ; Luo S; Li G; Zhang Y; Laporte J; Perrella MA; Liu X; Agrawal PB
JCI Insight; 2022 Aug; 7(15):. PubMed ID: 35763354
[TBL] [Abstract][Full Text] [Related]
38. Mutant BIN1-Dynamin 2 complexes dysregulate membrane remodeling in the pathogenesis of centronuclear myopathy.
Fujise K; Okubo M; Abe T; Yamada H; Nishino I; Noguchi S; Takei K; Takeda T
J Biol Chem; 2021; 296():100077. PubMed ID: 33187981
[TBL] [Abstract][Full Text] [Related]
39. Imaging-based evaluation of pathogenicity by novel DNM2 variants associated with centronuclear myopathy.
Fujise K; Okubo M; Abe T; Yamada H; Takei K; Nishino I; Takeda T; Noguchi S
Hum Mutat; 2022 Feb; 43(2):169-179. PubMed ID: 34837441
[TBL] [Abstract][Full Text] [Related]
40. Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies.
Toussaint A; Cowling BS; Hnia K; Mohr M; Oldfors A; Schwab Y; Yis U; Maisonobe T; Stojkovic T; Wallgren-Pettersson C; Laugel V; Echaniz-Laguna A; Mandel JL; Nishino I; Laporte J
Acta Neuropathol; 2011 Feb; 121(2):253-66. PubMed ID: 20927630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
